At the IGTP TODAY
Recruitment for the clinical trial TÉSTATE PrEP has started. This clinical trial has been designed by the Centre for Epidemiological Studies on HIV/AIDS in Catalonia (CEEISCAT) to implement a pilot plan for online HIV/STI screening in PrEP users.
 - copia_1687953960.jpeg)
One of the most commonly practised cardiovascular health interventions, the coronary bypass, could undergo a revolutionary innovation with the joint research carried out by the Blood and Tissue Bank (BST), the Germans Trias i Pujol Research Institute (IGTP) and the Vascular Engineering and Applied Biomedicine Group (GEAB) of the IQS (URL). The three centres are working to develop a vascular graft from donor veins that can be used for bypass surgery to restore blood flow.
The research groups in Nursing Care (NURECARE) and Innovation, Health Economics and Digital Transformation (INEDIT) from the IGTP are leading the publication of the first report on the key factors for introducing digital technologies in professional nursing practice environments. Through this effort, professionals from the Germans Trias Hospital are participating for the first time in the design of a comprehensive analysis of the required changes, while also offering recommendations to ensure the success of any initiative aimed at incorporating these technologies into hospitals.
An international trial has investigated the potential immune-boosting effects of the tuberculosis BCG vaccine against COVID-19. The results show that the risk of developing the disease during the first six months after vaccination was not reduced in participants as originally hoped for. Nearly 4,000 healthcare workers took part in the BRACE trial across 36 sites from five countries, including the Germans Trias Hospital. Researchers from an IGTP tuberculosis research group were involved in the development of the study, which has been published in the New England Journal of Medicine.
A state-of-the-art super-resolution fluorescence confocal microscope, called Abberior Infinity, was installed in the high-level biosafety (NCB3) facility of the Centre for Comparative Medicine and Bioimage (CMCiB). The equipment of this class, unique in the region, is a powerful tool for anyone aiming to perform advanced microscopy studies on fully infectious Level 3 pathogens (HIV, SARS-CoV-2, Monkey Pox, TB etc.) The microscope is available for use by all internal and external users via IGTP Microscopy Platform.
A preclinical study with support from the Spanish Association Against Cancer has identified a potential treatment approach for patients with hepatoblastoma, which involves combining standard chemotherapy with a drug currently undergoing clinical trials. The research was conducted using patient samples and animal and laboratory models, and has been led by Dr Josep M. Llovet, professor at the UB and group leader at IDIBAPS, and Dr Carolina Armengol, group leader at IGTP and member of CIBEREHD.
Researchers from the Innate Immunity group at the Germans Trias i Pujol Research Institute (IGTP) have developed a new immunotherapy based on a monoclonal antibody directed against tumour macrophages. The results obtained lay the foundations for a new treatment for patients with lung cancer, with the potential to be applied to other solid tumours. The study has been published in the journal eBioMedicine.
_1683206318.jpg)
The Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) has published the final resolution of the call for grants to support the activities of research groups in universities, centres and foundations. In this year's call, 21 IGTP groups have been recognised as Consolidated or Emerging Research Groups, 7 of which will receive funding totalling €340,000.
_1681823569.jpg)
The Hereditary Cancer research group from the Germans Trias i Pujol Research Institute (IGTP) has led an international collaboration that has allowed the genomic characterisation of the most commonly used cell lines derived from malignant peripheral nerve sheath tumours (MPNSTs). This research has generated a detailed catalogue of genomic alterations for each cell line, which can be used to develop strategies for precision therapies. At the same time, a genomic repository has been created that is open to all researchers interested in these tumours. The work has been published in the journal iScience.
A multidisciplinary group of tuberculosis experts from the TBnet and RESIST-TB networks have reached a consensus on key issues related to the molecular prediction of Mycobacterium tuberculosis antibiotic sensitivity or resistance and its clinical implications. The consensus document provides guidance for the design of therapeutic regimens and the optimization of treatments, and is intended to help clinicians manage tuberculosis patients. The paper, published in The Lancet Infectious Diseases and led by Dr José Domínguez from IGTP, is an update of a similar statement made in 2016.
_1678377436.JPG)